Tag: INNV

Source: TradeTheNews

Upside

– $VTGN +59.5% (extends the prior-session rally after preliminary PALISADE-4 open-label extension data for fasedienol in social anxiety disorder)

– $GRML +24.0% (no clear fresh catalyst identified; exceptionally heavy-volume small-cap move)

– $WOR +15.5% (Q1 beat as stronger Building Products results and data-center demand lifted performance)

– $TLSI +15.0% (FDA grants 510(k) clearance for the TriNav Advance drug-delivery device)

– $IONQ +13.0% (demonstrates an end-to-end real-time quantum error-correction decoder running on a standard CPU)

– $CBRL +9.0% (Q4 profit beat and FY27 EBITDA outlook pointed to a sharp recovery despite lower sales)

– $QUBT +4.0% (quantum-computing sympathy following IONQ’s error-correction milestone)

– $CART +3.0% (expands its AI-shopping partnership network)

– $APH +3.0% (Bernstein initiates coverage at Outperform)

Downside

– $JAGX -48.0% (reverses sharply after the prior session’s roughly twelvefold FDA-fee-waiver-driven surge)

– $INNV -8.5% (10M-share secondary offering by selling stockholders creates a near-term stock overhang)

– $VOYG -7.5% ($350M convertible-senior-notes offering raises dilution concerns)

– $ASTH -7.5% (no clear fresh catalyst identified; renewed selling follows the recent short report questioning accounting estimates)

– $BMEA -7.0% (launches an underwritten common-stock and pre-funded-warrant offering)

– $AU -4.5%, GFI -4.5%, AG -3.0%, NEM -2.0% (precious-metals miners fall as gold and silver prices retreat)

– $BABA -3.0% (China ADR weakness ahead of the U.S.-China summit as mainland equities decline)

– $APP -2.5% (extends the AI-disruption selloff on concern consumer agents could pressure ad-tech economics)